The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer

1 January 2003

book chapter
Published by Springer Nature

Vol. 116, 173-182
https://doi.org/10.1007/978-1-4615-0451-1_10

Abstract

The prognosis for patients with metastatic renal cell carcinoma (RCC) is poor. The median overall survival time of patients with advanced disease is approximately 10 months with a 3-year survival rate of about 10%¹. RCC is typically described as chemotherapy (and radiation therapy) resistant. Most authors agree that biologic response modifiers (i e immunotherapy) represent standard first-line treatment for advanced RCC.

Keywords

This publication has 61 references indexed in Scilit:

PTENMMAC1TEP1 mutations in human primary renal‐cell carcinomas and renal carcinoma cell lines
International Journal of Cancer, 2001
Experimental and Clinical Efficacy of 2′,2′-Difluorodeoxycytidine (Gemcitabine) against Renal Cell Carcinoma
Oncology, 1996
Phase II study of vinblastine and doxorubicin in advanced renal cell carcinoma
European Journal Of Cancer, 1994
Immunocytochemical Detection of P-Glycoprotein: Initial Expression Correlates with Survival in Renal Cell Carcinoma Patients
Oncology, 1994
New formulation intravenous melphalan in the treatment of patients with metastitic renal cancer
Investigational New Drugs, 1993
Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma
Investigational New Drugs, 1992
Phase II study of navelbine in advanced renal cell carcinoma
European Journal of Cancer and Clinical Oncology, 1991
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas
European Journal of Cancer and Clinical Oncology, 1984
Mitoxantrone in advanced renal cancer: A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group
European Journal of Cancer and Clinical Oncology, 1984
Vindesine in advanced renal cancer. A study of the EORTC genito-urinary tract cancer cooperative group
European Journal of Cancer and Clinical Oncology, 1983